Close Menu

In this week's Nature, University of California, Berkeley, researcher and CRISPR/Cas9 pioneer Jennifer Doudna and colleagues present data giving new insights into how the genome-editing technology zeroes in on its target. They found that the conformational state of the nuclease domain that cleaves target DNA strands directly controls the cutting activity. The discovery highlights a "proofreading mechanism" that serves as a final checkpoint before DNA double-strand break formation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.